We are live on ! Find out more
NRXP icon

NRX Pharmaceuticals

19 hedge funds and large institutions have $1.29M invested in NRX Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 2 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 2

62% more call options, than puts

Call options by funds: $212K | Put options by funds: $131K

4.46% more ownership

Funds ownership: 0.4%4.86% (+4.5%)

27% less capital invested

Capital invested by funds: $1.76M → $1.29M (-$475K)

39% less funds holding

Funds holding: 3119 (-12)

73% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 15

Holders
19
Holders Change
-12
Holders Change %
-38.71%
% of All Funds
0.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
11
Reduced
2
Closed
15
Calls
$212K
Puts
$131K
Net Calls
+$81K
Net Calls Change
+$45K
Name Holding Trade Value Shares
Change
Change in
Stake
Jane Street
26
Jane Street
New York
-$13.1K -2,769 Closed
UAS
27
United Asset Strategies
New York
-$8.64K -1,830 Closed
LPL Financial
28
LPL Financial
California
-$6.88K -1,457 Closed
Bank of New York Mellon
29
Bank of New York Mellon
New York
-$4.78K -1,013 Closed
IC
30
IEQ Capital
California
-$4.72K -1,000 Closed
Osaic Holdings
31
Osaic Holdings
Arizona
-$472 -100 Closed
Group One Trading
32
Group One Trading
Illinois
-$428 -91 Closed
Simplex Trading
33
Simplex Trading
Illinois
-$71 -20 Closed
Fidelity Investments
34
Fidelity Investments
Massachusetts
-$52 -11 Closed

NRXP Hedge Fund Activity: Q2 2024 in Review

19 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q2 2024, worth a combined $1.29M — down 27% from $1.76M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of NRXP and 4 opened new positions — a net loss of 11 holders — while 2 trimmed existing stakes and 11 added.

The largest buyer was Vanguard Group, adding an estimated $343K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $89K sold.

  • 19 institutional investors held NRX Pharmaceuticals (NRXP) as of Q2 2024, down from 31 in Q1 2024.
  • Funds reported $1.29M of NRX Pharmaceuticals stock for Q2 2024, down 27% quarter-over-quarter.
  • 4 funds opened new NRX Pharmaceuticals positions in Q2 2024 and 15 closed out, a net change of -11 holders.
  • The largest NRX Pharmaceuticals buyer in Q2 2024 was Vanguard Group, an estimated $343K added.
  • The largest NRX Pharmaceuticals seller in Q2 2024 was Renaissance Technologies, an estimated $89K sold.

Based on aggregated 13F filings for Q2 2024.